VERTEX PHARMACEUTICALS AND CYSTIC FIBROSIS FOUNDATION THERAPEUTICS ENTER COLLABORATION

Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) today announced that they have entered into a new collaboration to accelerate clinical development of VX-770, a novel, oral drug candidate for the treatment of cystic fibrosis (CF). CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

CNW Group (http://www.newswire.ca/en/releases/archive/March2006/23/c5167.html)